• Reframing p53 Reactivation: RG7388 and Translation

  2026-09-25

  MDM1 and MDM2 influence p53 through distinct mechanisms, creating a useful translational framework—not proof of interchangeability—for studying p53-dependent treatment response. This article connects colorectal chemoradiotherapy findings with RG7388 research and outlines experiments that can test where MDM2 antagonism may add value.

• Urolithin A and Metabolic Control in Fibrosis Research

  2026-09-25

  Explore how Urolithin A–linked mitochondrial quality control differs from glutamine metabolism in hepatic stellate cells. This mechanistic comparison helps researchers design assays that distinguish organelle renewal from metabolic fuel dependence without implying an untested antifibrotic effect.

• Reactive Oxygen Species Assay Kit: Live-Cell Guide

  2026-09-24

  Learn how to plan and interpret live-cell oxidative stress measurements with the Reactive Oxygen Species Assay Kit (SKU K2065). This scenario-based guide explains the DCFH-DA fluorescent probe workflow, practical controls, interpretation limits, and evidence-informed kit selection.

• Protease Inhibitor Cocktail: Assay-Safe Use

  2026-09-24

  Learn when protein degradation can compromise cell-based assay follow-up, Western blots, co-immunoprecipitation, and phosphorylation analysis—and when it cannot explain a live-cell viability result. This scenario-driven guide covers the formulation, 1:100 use, and compatibility considerations for Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO), SKU K1010.

• Ribociclib pH Shifts: A QbD Interaction Assessment

  2026-09-23

  A Quality by Design analytical method and biorelevant micro-dissolution study examined whether pH shifts associated with acid-reducing therapy could materially affect ribociclib succinate solubility. Although measured solubility decreased after the modeled shifts, the authors concluded that the changes did not indicate a significant effect under the tested conditions, while emphasizing the value of dynamic in vitro assessment.

• Merbromin as a Mixed-Type SARS-CoV-2 3CLpro Inhibitor

  2026-09-23

  A high-throughput biochemical study identified Merbromin as a selective mixed-type inhibitor of the SARS-CoV-2 main protease, 3CLpro. Its combination of activity-based screening, kinetic analysis, binding measurements, and molecular docking provides a useful framework for evaluating repurposed compounds while also defining the limits of biochemical evidence.

• Baicalin methyl ester: Assay Design Guide

  2026-09-22

  A scenario-based guide to using Baicalin methyl ester (SKU N2884) in cell viability, proliferation, and LPS-induced intestinal barrier damage research. It covers concentration selection, solvent compatibility, controls, mechanistic readouts, and practical product-selection criteria supported by product data and literature.

• LAG-3–TCR Proximity in T Cell Suppression

  2026-09-22

  A 2025 Cell study shows that LAG-3-mediated inhibition depends not only on MHC class II binding but also on spatial proximity to the T cell receptor. By linking LAG-3 and the TCR with an Fc-attenuated bispecific antibody, the authors achieved broad T cell suppression and reduced autoimmune disease in mouse models, while identifying a CD3ε/Lck signaling mechanism.

• Mavorixafor in WHIM Syndrome: Phase 3 Evidence

  2026-09-21

  The reference commentary highlights a placebo-controlled phase 3 trial showing that oral CXCR4 inhibition with mavorixafor can extend neutrophil and lymphocyte availability and reduce infections in WHIM syndrome. Its main contribution is the translation of disease mechanism into a practical, sustained treatment strategy while also identifying unresolved questions about long-term safety, immune restoration, and cancer risk.

• 8-Chloroadenosine: Reliable RNA Assays

  2026-09-21

  A practical, scenario-driven guide to using 8-Chloroadenosine (SKU B7667) in RNA synthesis, viability, proliferation, and cytotoxicity workflows. It addresses stock preparation, dose–time design, interpretation of IL-6 and lncRNA experiments, and evidence-based product selection.

• 6C Medium Preserves Mouse Corneal Epithelial Growth

  2026-09-20

  An et al. developed a serum-free, feeder-free 6C culture system that combines six pathway modulators with keratinocyte calcium to prolong mouse corneal epithelial cell proliferative activity. By limiting epithelial-to-mesenchymal changes while retaining progenitor-associated markers, the approach improves generation of epithelial populations for wound-healing and regenerative-medicine studies.

• Phillygenin and Signaling in Diabetic Nephropathy

  2026-09-19

  The reference study identifies phillygenin as a potential intervention for diabetic nephropathy and links its protective effects to coordinated suppression of TLR4/MyD88/NF-κB inflammation and restoration of PI3K/AKT/GSK3β signaling. By combining high-glucose podocyte experiments, RNA sequencing, biochemical assays, and db/db mouse studies, it provides a preclinical framework for connecting reduced inflammation and apoptosis with improved renal function.

• Boc-D-FMK Workflows for Apoptosis Research

  2026-09-18

  Boc-D-FMK is a cell-permeable pan-caspase inhibitor for separating caspase-dependent apoptosis from upstream inflammatory signaling. This practical guide combines product-supported treatment conditions with renal, hepatic, and fibrosis-oriented assay strategies, while clearly distinguishing validated use from hypothesis-generating applications.

• Gallein and the Next Frontier of GPCR Translation

  2026-09-18

  Gallein offers translational researchers a way to interrogate G protein βγ-dependent signaling across cancer, immunity, cardiac inflammation, and emerging metabolic biology. By connecting validated preclinical applications with the lactate–GPR81/FARP1–RAC1 axis, this article outlines a rigorous strategy for testing whether Gβγ signaling contributes to insulin-independent glucose uptake without overstating current evidence.

• Protease Inhibitor Cocktail: EDTA-Free Workflow

  2026-09-17

  Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) helps limit endogenous proteolysis during protein extraction and sample preparation for Western blotting, co-immunoprecipitation, pull-downs, and phosphorylation-sensitive assays. It should not be treated as a complete phosphatase inhibitor system or used without compatibility testing in DMSO-sensitive assays and workflows that intentionally measure protease activity.

7829 records 1/522 page Next 12345 下5页 Last page